Lymphoma Clinical Trials

Showing 341-360 of 1,633 trials

9-ING-41 in Pediatric Patients With Refractory Malignancies.

NCT04239092

9-ING-41 has anti-cancer clinical activity with no significant toxicity in adult patients. This Phase 1 study will study its efficacy in paediatric patients with advanced malignancies.

Refractory CancerRefractory NeoplasmCancer Pediatric+8 more

Actuate Therapeutics Inc.40 participantsStarted Jun 2020

San Francisco, California, United States • Aurora, Colorado, United States • Chicago, Illinois, United States +6 more locations

COMPLETEDPHASE2/PHASE3

A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

NCT02763319

The purpose of the study is to compare the safety and efficacy of Tafasitamab with BEN versus RTX with BEN in adult patients with relapsed of refractory DLBCL.

Diffuse Large B-cell Lymphoma

Incyte Corporation453 participantsStarted Nov 2016

Anaheim, California, United States • Bakersfield, California, United States • Burbank, California, United States +155 more locations

9-ING-41 in Pediatric Patients With Refractory Malignancies.

A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Related Searches

A Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Evaluation of Skin Tests in Biotherapy Allergies

A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors

Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL)

New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma

Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight

Expectations and Priorities of Elderly Patients for a First Medical Treatment for Cancer

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation

Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma

Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases

CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas

The PACMAN-Hu19 Trial: a Study of the Safety and Feasibility of Locally Produced, CD19-targeted and Human CAR T-cell Therapy in Children and Young Adults With Relapsed or Refractory B-cell Malignancies

Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma